Scientists have demonstrated that a new blood test can accurately predict the presence of beta-amyloid plaques in the brain, according to a new study funded in part by NIA. Published in Neurology, the study analyzed the ability of a blood test to predict the presence of Alzheimer’s disease-associated protein beta-amyloid in the brain. The new blood test, which performs comparably to existing brain scan- or spinal tap-based tests, could lower costs and expand the availability of diagnostic studies for Alzheimer’s disease.
Alzheimer’s is characterized by the buildup of a protein called beta-amyloid, which forms sticky plaques on the brain and can cause brain cells to die. Testing for the presence of these amyloid plaques on the brain is an important part of Alzheimer’s diagnosis and research. For people experiencing memory problems, checking for amyloid in the brain helps health care providers determine whether Alzheimer’s is the potential cause. It also can help doctors determine which patients will respond to drugs that target amyloid. For people without any signs of dementia, the presence of amyloid plaques on the brain may help researchers enroll participants in clinical trials for treatments to prevent or delay the onset of cognitive symptoms.